Ex-Brazil President Rousseff hospitalized in Shanghai, Brazilian media reports
Rousseff, 77, was tapped to lead the New Development Bank (NDB) in 2023. Folha reported she was hospitalized at the Shanghai East International Medical Center after presenting high blood pressure, vomiting and dizziness on Friday.
The NDB, which is headquartered in the Chinese city, did not immediately respond to a request for comment outside normal business hours.
The Shanghai East International Medical Center and a representative of Rousseff could not be immediately reached for comment.
Rousseff, Brazil's first woman president, ran the country from 2011 until being impeached in 2016 during a harsh recession and falling from power.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Deaf people are regaining their hearing thanks to groundbreaking new treatment
A new gene therapy could restore hearing in deaf children and adults, a groundbreaking study suggests. Researchers from several Chinese hospitals looked at 10 patients who were either born deaf or developed severe hearing loss due to a genetic mutation. All of them, who ranged from infants to young adults, were injected one time with modified version of adeno-associated viruses (AAV). The viruses are not meant to spread disease but instead help deliver gene therapies to cells. The researchers found the treatment improved hearing in all 10 participants within a year, and most noticed a difference in just one month. On average, sounds only needed to be half as loud as previously played for participants to pick them up. Young children had the most significant improvements. One seven-year-old deaf girl was able to hold a conversation with her mother four months after treatment. The shot is thought to help restore functional copies of the OTOF gene, which helps transmit sound and was mutated in all of the participants. The team suspects the study 'is just the beginning' in developing treatments for the 200,000 deaf people worldwide who have a mutation in their OTOF gene. Maoli Duan, study author and consultant docent at the Karolinska Institutet in Sweden, said: 'This is a huge step forward in the genetic treatment of deafness, one that can be life-changing for children and adults.' The study, published Wednesday in the journal Nature Medicine, included 10 people ages one to 24 with either congenital deafness - meaning they were born with it - or severe hearing impairment. All participants had mutations of their OTOF gene, which provides instructions for making the protein otoferlin. Otoferlin helps transmit sound from the inner ear to the auditory nerve. Each participant received hearing and genetic testing prior to the experiment. All of the participants received injections containing two AAV viruses in the cochlea of each of their ears. The cochlea is a fluid-filled cavity in the inner ear that converts auditory vibrations into electrical signals, which the brain interprets as sound. Before treatment, participants on average could only hear sounds at least 106 decibels, about the volume of a motorcycle, car horn or sporting event. After a year, they were able to hear sounds 52 decibels or louder, the same as a normal conversation. The seven-year-old girl in the study went from only being able to hear 101 decibels to 40 after only two weeks. Within two months, she could detect sounds above 25 decibels, about the volume as a whisper. After four months, the girl could have daily conversations with her mom with no assistive hearing devices. Only one participant was an adult, about 24 years old. The treatment allowed him to identify certain spoken words and the sound of hands clapping after several months. Dr Duan said: 'Smaller studies in China have previously shown positive results in children, but this is the first time that the method has been tested in teenagers and adults, too. 'Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.' There were also no severe adverse reactions to the injections. Experts believe the injections may have helped provide the bodies of participants with functional copies of mutated genes, which may have helped their OTOF genes produce more otoferlin needed for hearing. OTOF mutations account for about two to eight percent of genetic deafness cases. Dr Duan said the new treatment 'is just the beginning.' She added: 'We and other researchers are expanding our work to other, more common genes that cause deafness, such as GJB2 and TMC1. These are more complicated to treat, but animal studies have so far returned promising results. 'We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment.'
Reuters
13 hours ago
- Reuters
US FDA approves Regeneron's blood cancer therapy
July 2 (Reuters) - The U.S. Food and Drug Administration has approved Regeneron's (REGN.O), opens new tab cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer. The FDA's nod for the therapy, branded Lynozyfic, comes after a setback last year when the regulator declined to approve it after an inspection at a third-party manufacturer. Lynozyfic was greenlit by the regulator to treat patients with multiple myeloma who have received at least four prior lines of therapy. Multiple myeloma is a commonly recurring cancer. Over 36,000 new cases are estimated to be diagnosed in the U.S. in 2025, according to the American Cancer Society.
Reuters
15 hours ago
- Reuters
Health Rounds: 3D printed insulin-producing cells show promise for type 1 diabetes in lab tests
July 2 (Reuters) - Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress, opens new tab underway in London. Using a bio-ink made from human pancreatic tissue from which all cellular components had been removed, and alginate - a substance derived from seaweed - they printed human pancreatic islet cells. The printed cells remained alive and functional in test tubes for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use, the researchers said. While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells, the bio-ink retains key components of that extracellular matrix, thereby improving the cells' survival and function, the researchers said. The printed cells were more efficient than standard islet cell preparations at releasing insulin when exposed to glucose. By day 21, the bio-printed islets showed a stronger ability to sense and react to blood sugar levels, and they maintained their structure without clumping or breaking down. In traditional islet-cell transplants, done in patients with type 1 diabetes who experience dangerous and unpredictable low blood sugar episodes, islet cells from human donors are infused into the liver. The 3D-printed islets would be implanted under the skin using local anesthesia and a small incision, which could be safer and more comfortable option for patients, the researchers said. The team is now testing the bio-printed cells in animals and exploring long-term storage options that could make the therapy widely available. 'This is one of the first studies to use real human islets instead of animal cells in bio-printing, and the results are incredibly promising,' study leader Quentin Perrier of Wake Forest University School of Medicine in North Carolina said in a statement. 'It means we're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections.' GENE EDITING BREAKTHROUGH IN CELLS' ENERGY FACTORIES Incurable disorders of mitochondria, the energy-producing 'factories' inside of cells, may one day be addressed by gene therapies, lab experiments suggest. Mitochondria – specialized structures within cells - have their own DNA, separate from the DNA in the cell's nucleus. Mutations in mitochondrial DNA can cause a variety of debilitating conditions affecting multiple organs, particularly those that require high energy, such as the brain, liver, heart, muscles, and kidneys. Existing gene editing tools like CRISPR have not been useful for these disorders because they can't efficiently pass through the mitochondrial membranes. 'Using a new kind of gene editing tool, we were able to fix DNA mistakes that cause mitochondrial disease,' said study leader Dr. Martijn Koppens from the University Medical Center Utrecht in the Netherlands. To cut and paste pieces of DNA, the new tool uses different mechanisms and components than CRISPR. For example, instead of the Cas protein, the new tool, called DdCBE, uses an inactive version of a bacterial toxin as its molecular scissors. To deliver the 'scissors' to the mitochondria, the tool uses mRNA encapsulated in tiny lipid particles, a transport method also used to deliver COVID-19 vaccines. As reported in PLoS Biology, opens new tab, Koppens' team successfully used their tool to introduce a mutation into a gene in liver cell mitochondria, thereby disrupting energy production in the cells. They were also able to correct a mutation in mitochondria from a patient with a genetic kidney disorder. 'I envision that in the near future, mitochondrial gene editing will be used to generate accurate mitochondrial disease models, which will transform basic research as well as therapy development,' Koppens said. Blood thinner therapy need not be delayed in most patients with a recent stroke attributable to an irregular heartbeat, according to a new analysis. Pooling data from four randomized trials involving nearly 5,500 patients with atrial fibrillation and a recent stroke, researchers found that starting direct oral anticoagulants - which prevent formation of blood clots - within four days was safe and effective. These drugs include Johnson & Johnson's (JNJ.N), opens new tab Xarelto or Eliquis from Bristol Myers Squibb (BMY.N), opens new tab and Pfizer (PFE.N), opens new tab. Atrial fibrillation can lead to blood clots in the heart that dislodge and travel to the brain, causing a stroke. Blood thinners can prevent clots, but they also increase the risk of bleeding in the brain, so it has been common practice to hold off for a while after a stroke before starting them. Based on the safety observed in the current analysis, 'the benefits of early initiation of blood-thinning treatment are clear," study leader Nick Freemantle of University College London said in a statement. "This approach ensures that crucial treatments are not delayed or missed, particularly for patients who are discharged from the hospital." Patients were split into two groups, with 2,691 receiving the blood thinners within 4 days and 2,750 starting the pills on day 5 or later. The incidence of either recurrent strokes from blood clots or strokes from bleeding in the brain was 2.1% with early anti-coagulation administration and 3.0% with delayed treatment, researchers reported in The Lancet, opens new tab. There was no increase in brain bleeding in the early-treatment group. However, few patients in the trial had experienced strokes that extensively damaged the brain, which would have increased the bleeding risks associated with starting the blood thinners right away. An editorial, opens new tab published with the study concludes that overall, the findings favor early initiation of oral anticoagulation in patients with strokes related to atrial fibrillation, especially those with smaller amounts of brain damage. However, the editorial noted some additional factors for providers to consider. 'Adherence to strict predefined early or late initiation thresholds might oversimplify the complexity" of deciding when to start blood thinners, it noted. It said there should be an assessment of other co-morbidities, including advanced age, other medications being taken and frailty, when delayed blood thinner therapy "might derive increased benefit.' (To receive the full newsletter in your inbox for free sign up here)
